Allergy Therapeutics plc has been mentioned in a Form 8.5 (EPT/RI) disclosure by Panmure Gordon (UK) Limited. The disclosure states that Panmure Gordon (UK) Limited, as an exempt principal trader, has made purchases and sales of Allergy Therapeutics' 0.1p ordinary shares. The purchases amounted to 887,819 securities, with the highest price per unit paid at 0.013375 and the lowest price per unit paid at 0.01316. On the other hand, the sales totaled 694,027 securities, with a price per unit of 0.0144.
The disclosure does not mention any cash-settled derivative transactions or stock-settled derivative transactions, including options, related to Allergy Therapeutics. It also states that there are no indemnity or option arrangements, agreements, or understandings between Panmure Gordon (UK) Limited and any party to the offer or any person acting in concert with a party to the offer.
The disclosure was made on October 26, 2023, and the contact person for further information is Freddie Wooding, with a telephone number of +44 (0)20 7886 2969. The disclosure was made in accordance with Rule 8 of the Takeover Code and must be made to a Regulatory Information Service. The Market Surveillance Unit of the Panel is available for consultation regarding the Code's dealing disclosure requirements.